Latest Breaking News On - Coeptis pharmaceuticals - Page 1 : comparemela.com

Coeptis Therapeutics Dr Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

Coeptis Therapeutics Dr Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesColleen delaneyKarolinska institutetUniversity of pittsburghPanel discussionPrnewswire coeptis therapeutics holdings incSecurities exchangeCoeptis therapeutics incExchange commissionCoeptis pharmaceuticals incCoeptis therapeutics holdings incCompany or coeptisDrug administrationTherapeutics holdingsAllogeneic cell therapies summitAnnual meeting

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesBritish columbiaDave mehalickCarrie stoltzmanBraxton jamisonDan yeraceColleen delaneyLara ionescu silvermanEmily hsiehKarolinska institutetExchange commissionInternational society for cell gene therapyInternational symposium on cellSecurities exchangeCoeptis therapeutics holdings incDrug administration

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor s Distinguished Research Award

WEXFORD, Pa., April 2, 2024 /PRNewswire/ Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and.

Karolinska institutetAlexander deitersDave mehalickExchange commissionCoeptis therapeutics incCoeptis pharmaceuticals incSecurities exchangeUniversity of pittsburghKennethp dietrich school of artsPrnewswire coeptis therapeutics holdings incHoldings incResearch awardDrug administrationCoeptis therapeutics holdings incTherapeutics holdingsProfessor alexander deiters

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and.

Dave mehalickKarolinska institutetDaniel kontoh boatengDavid schemeliaColleen delaneyCoeptis therapeutics holdings incCoeptis pharmaceuticals incPrnewswire coeptis therapeutics holdings incCoeptis therapeutics incHoldings incWorld health organizationDrug administrationExchange commissionSecurities exchangeUniversity of pittsburghTiberend strategic advisors inc

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave.

Dave mehalickDaniel kontoh boatengColleen delaneyKarolinska institutetDavid schemeliaSecurities exchangeExchange commissionKarolinska instituteCoeptis therapeutics holdings incCompany or coeptisDeverra therapeutics incPrnewswire coeptis therapeutics holdings incHoldings incDrug administrationCoeptis therapeutics holdingsUniversity of pittsburgh